Liver Injury Risk Linked to Tolvaptan Prompts FDA Warning
The FDA has issued a drug warning regarding a possible risk of "significant" liver injury associated with the use of the selective vasopressin V2-receptor antagonist tolvaptan (Samsca). The agency is urging clinicians to conduct liver tests promptly in patients who report symptoms that may indicate liver injury.
Source: AAFP Health of the Public - Category: Primary Care Source Type: news
More News: American Academy of Family Physicians (AAFP) | Health | Liver | Primary Care | Urology & Nephrology | Warnings